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The tissue or glandular kallikreins (KLK) are mem-
bers of a highly conserved multigene family encoding
serine proteases that are central to many biological pro-
cesses. The rodent KLK families are large, highly con-
served and clustered at one locus. The human KLK gene
family is clustered on chromosome 19q13.3–13.4, and un-
til recently consisted of just three members. However,
recent studies have identified up to 11 new members of
the KLK family that are less conserved than their rodent
counterparts. Using a Southern blot and sequence anal-
ysis of 10 BACs and cosmids spanning approximately
400 kilobases (kb) either side of the original KLK 60-kb
locus, we demonstrated that these genes also lie adja-
cent to this. We have also clarified the position of several
microsatellite markers in relation to the extended KLK
locus. Moreover, from Southern blot analysis of the cos-
mids and BACs with a degenerate oligonucleotide probe
to the histidine-encoding region of serine proteases, we
have shown that there are no other serine protease
genes approximately 400 kb centromeric and 220 kb te-
lomeric of the extended locus. We performed an exten-
sive analysis of the expression patterns of these genes by
poly(A)1 RNA dot blot and reverse transcriptase-polym-
erase chain reaction analysis, and demonstrated a di-
verse pattern of expression. Of interest are clusters of
genes with high prostate (KLK2–4) and pancreatic
(KLK6–13) expression suggesting evolutionary conser-
vation of elements conferring tissue specificity. From
these findings, it is likely that the human KLK gene
family consists of just 14 clustered genes within 300 kb
and thus is of a comparable size to the rodent families
(13–24 genes within 310 and 480 kb, respectively). In
contrast to the rodent families, the newest members of
the human KLK family are much less conserved in se-
quence (23–44% at the protein level) and appear to con-
sist of at least four subfamilies. In addition, like the rat,
these genes are expressed at varying levels in a diverse
range of tissues although they exhibit quite distinct pat-
terns of expression.
Serine proteases are a group of protein-cleaving enzymes
that contain a serine residue in their active site and play
important roles in diverse physiological processes. The glandu-
lar or tissue kallikreins are a subgroup of serine proteases
highly conserved across several species, that are involved in
the post-translational processing of polypeptides to their bio-
active or inactive forms, a function that underlies and is central
to most biological events (1). Tissue kallikrein (encoded by
KLK1),1 from which this family derives its generic name, pro-
cesses kininogen to release (lys)-bradykinin, a multifunctional
peptide involved in the regulation of local blood flow, sodium
balance, inflammation, and cell proliferation in many tissues
(2). Other members of the KLK family include growth factor
processing enzymes such as mouse epidermal growth factor-
binding protein, g-nerve growth factor, and enzymes that gen-
erate vasoactive peptides such as the mouse pro-renin convert-
ing enzymes, g-renin, and rat tonin (3–5). In man, the two other
most well characterized enzymes, prostate-specific antigen,
PSA (encoded by KLK3; Ref. 6), and hK2 (encoded by KLK2;
Ref. 7), act on entirely different substrates. Nevertheless, each
is involved in the selective cleavage of specific precursors to
their bioactive or inactive forms (8). These findings highlight
the involvement of the KLK family in a number of different and
complex enzymic pathways that underlie several important
biological functions.
The wide range of potential functions of these enzymes is
emphasized by their diverse, yet specific, tissue expression
patterns. Whereas KLK2 and KLK3 are primarily expressed at
high levels in the secretory epithelium of the prostatic ducts
and have been implicated in normal prostatic function as well
as in cancer progression (8), tissue kallikrein, through its mul-
tifunctional roles, is involved in the (patho)physiology of the
kidney, brain, and respiratory, gastrointestinal, and reproduc-
tive tracts (2). This diverse functionality is underscored by the
ubiquitous expression pattern observed for KLK1 in the rat (9).
Although a function has not yet been ascribed to the protein
products of most other rat KLK genes, an indication of the
tissue in which they will be functional is gained from their
tissue expression patterns (9). In man, the newly identified
KLK serine proteases, Protease M/neurosin/zyme (10–12) and
normal epithelial cell-specific 1 (Nes1)2 (13), are highly ex-
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pressed in brain and breast tissue, and have been suggested to
be involved in Alzheimer’s disease and breast cancer, respec-
tively (12–14). Several other recently identified KLK-like ser-
ine protease genes have also been shown, at the RT-PCR level,
to be expressed in a tissue-specific manner, which presumably
indicates the tissues in which they will be biologically active
(15–20).
The KLK1, KLK2, and KLK3 genes are clustered within a
region that spans 60 kb on chromosome 19q13.3-13.4 (21, 22).
This cluster maps to a position ;55.5 Mb from the p-telomere
on the metric physical map of the chromosome and at the
proximal end of 19q13.4. The larger size of the rat and mouse
KLK gene families (13–24 genes) (23–25), which are also clus-
tered in one locus (23, 25, 26), and the recent identification of a
new KLK gene, KLK4 (prostase/KLKL1) (15, 21, 27) 25 kb
downstream of the KLK2 gene (15, 21), suggested that the
human KLK gene family would be larger than previously
thought. Indeed, Southern blot analysis of a human genomic
library, using a monkey KLK cDNA with 92–95% homology to
human KLK cDNAs (28), indicated that there may be as many
as 19 human KLK genes (29). Furthermore, a number of KLK-
related serine protease gene sequences have been detected that
lie telomeric to the original KLK locus, thus expanding the
human KLK gene family (30). However, the physical mapping
of this locus has not yet been described and the definitive size
of the family is not clear. In addition, the location of the various
microsatellite markers in the KLK locus is not clear.
In this study, we have physically mapped the serine protease
genes clustered at the KLK locus and defined the position of
key microsatellite markers. We have also confirmed the order
and orientation of the 10 putative new members of the human
KLK family which span approximately 300 kb across the KLK
locus on chromosome 19q13.4. We have further determined
that no other serine protease genes are present within the
regions surrounding the KLK locus. In addition, extensive gene
expression studies have identified the most abundant sites of
expression for these genes and a diverse tissue specificity of
expression similar to the rodent KLK family. Also, phylogenetic
analysis of the 14 serine proteases encoded by the KLK genes of
this locus demonstrated the extent of divergence within the
expanded family and suggested that there are at least four
human KLK subfamilies.
EXPERIMENTAL PROCEDURES
Cosmid and BAC DNA Clones—Four cosmids (R32740, R31381,
F22702, and R28781) and six BAC clones (BC772576, BC778306,
BC33747, BC85745, BC349237, and BC892989), that spanned the clas-
sical KLK locus (KLK1–3) and approximately 400 kb either side of this
region, were used in the following studies. Five hundred-ml cultures of
Luria-Bertani medium supplemented with 20 mg/ml kanamycin or 15
mg/ml chloramphenicol, were inoculated with the BAC and cosmid
clones, respectively, and incubated overnight at 37 °C. DNA was then
extracted using the alkaline lysis method, followed by RNase A diges-
tion and ethanol precipitation.
Physical Mapping of the KLK Locus on Chromosome 19q—Twenty mg
of DNA from the set of 10 BAC and cosmid clones were digested
overnight at 37 °C with the restriction enzyme EcoRI, then separated
electrophoretically on a 1% agarose gel. The gel was treated with 1.5 M
NaCl, 0.5 M NaOH for 30 min to denature the DNA, rinsed briefly in
distilled water, followed by a 30-min incubation in neutralization buffer
(1.5 M NaCl, 0.5 M Tris-HCl, pH 7.4). The DNA was capillary blotted
onto Hybond NTM nylon membrane (Amersham Pharmacia Biotech)
overnight in 20 3 SSC then cross-linked to the membrane by ultraviolet
irradiation. Membranes were hybridized with a 32P-random labeled
cDNA probe (Ambion), or a 32P-end labeled gene-specific oligonucleotide
probe (Table I), or a 32P-end labeled degenerate oligonucleotide probe to
the highly conserved regions spanning either the catalytic histidine
codon (GGTSCTSACAGCYGCCCAYTG; 16-fold degeneracy; S 5 G or
C, Y 5 C or T) or the the catalytic serine codon (CAGIGGICCIC-
CIGARTCAAC; 512-fold degeneracy; I 5 inosine, r 5 A or G) charac-
teristic of serine proteases. Hybridization was performed overnight in
ExpressHybTM solution (CLONTECH) at 42 or 55 °C for oligonucleotide
and cDNA probes, respectively. Blots were washed in 1 3 SSC, 0.5%
SDS up to 55 °C, then exposed to x-ray film (AGFA Curix Ortho) at
280 °C.
Computer Analysis of Chromosome 19 Sequences—Approximately
320 kb of draft sequence of chromosome 19q13.3-13.4 (available at the
Lawrence Livermore National Laboratory and the DOE Joint Genome
Institute website), beginning ;50 kb upstream of where two of the
original KLK genes (KLK2–3) were localized and searched with the
conserved peptide sequences spanning the catalytic histidine, aspar-
tate, and serine residues of KLK serine proteases (WVLTAAHC,
HDLMLLKL, and GDSGGPL; catalytic residue underlined). This was
performed using the data base creating tool and the tBLASTN algo-
rithm available at the Australian National Genome Information Ser-
vice. In addition, the cDNA sequence of each of the serine proteases,
KLK1 (accession number X13561), KLK2 (accession number S39329),
KLK3 (accession number M26663), KLK4 (accession number
AF113141), KLK51 (KLKL2, accession number AF135028), KLK6 (Pro-
tease M, accession number U62801), KLK7 (SCCE, accession number
L33404), KLK8 (neuropsin, accession number AB009849), KLK9
(KLKL3, accession number AF135026), KLK10 (Nes1, accession num-
ber AF024605), KLK11 (TLSP, accession number AB012917), KLK12
(KLKL5, accession number AF135025), KLK13 (KLKL4,accession num-
ber AF135024), and KLK14 (KLKL6, accession number AF161221), was
aligned against this genomic sequence using the BLASTN algorithm
available at the National Center for Biotechnology Information website.
BLASTN searches were also performed against the draft chromosome
19q13.3-13.4 sequence using microsatellite marker sequences between
272.77 and 276.46cR3000 at interval D19S425-D19S418. Marker se-
quences used were: WI-9055 and M21896, U37672, stSG39975, sts-
S39329, WI-20869, stSG30247, stSG32045, stSG1457, stSG3375,
stSG372, sts-H71236, SGC35527, U37672, stSG30429, sts-AA028917,
and L12214. The computer software DNAStar (Lasergene) was used to
construct an EcoRI restriction enzyme map of this sequence. These data
were then used in conjunction with the data obtained by physical
mapping and the EcoRI map available at the Lawrence Livermore
National Laboratory website to determine the exact position of each
gene and to reconstruct a definitive EcoRI map of this region.
Sequence and Phylogenetic Analysis—Multiple alignment of deduced
protein sequences was performed using the Eclustal tool available at
RT-PCR, reverse transcriptase-polymerase chain reaction; kb, kilo-
base(s); PSA, prostate-specific antigen.
TABLE I
Southern blot probes
Southern blot analysis of chromosome 19q cosmid/BAC EcoRI-di-
gested DNA was performed using 32P-end labeled oligonucleotide
probes for KLK5–8 and KLK10–12, and 32P random-labeled cDNA
probes for KLK9 and KLK13–14. Southern blot analysis of RT-PCR
products was performed using a digoxigenin-labeled oligonucleotide
probe. The percent difference in sequence between an individual probe
and each of the 14 genes for all probes used averaged 70%.
Gene DNA/oligonucleotide probes
KLK1/KLK1 59-CTGGACGTGGGCTTTTTCGCAC-39
KLK2/KLK2 59-TCTAAGGCTTTGATGCTTCAG-39
KLK3/KLK3 59-GGTATTTCAGGTCAGCCACAG-39
KLK4/KLK4 59-CTACCGTGCTGCAGTGCGTG-39
KLK5/KLKL2 59-AGTGCACTTGGGGGCTCTTGGTT-39
KLK6/protease M 59-TGTCCTGGTCATGGCTGGC-39 (RT-PCR)
59-AATCACCATCTGCTGTCTTGC-39
KLK7/SCCE 59-GCCCAGGTGCACGGTGTACTC-39
KLK8/Neuropsin 59-CAATGATCTGCCAGGCTGA-39 (RT-PCR)
59-GAGCCCCAGGATGTGATGCCC-39
KLK9/KLKL3 RT-PCR product (678 bp)
59-CCCCCAGCCTGAGATGAGACACT-39
KLK10/Nes1 59-GCCGTGGTGCCCCAGCCAGCA-39 (RT-PCR)
59-GGTAAACACCCCACGAGAGGA-39
KLK11/TLSP 59-GGTGATGGAGACTGGCGA-39
KLK12/KLKL5 59-AGGTCGTGCTCGTGGCTCGTC-39
KLK13/KLKL4 EST clone AA002101 EcoRI/HindIII digest
(1500 bp)
59-AGGGGTTAGGCGGTTGTTGTGG-39
KLK14/KLKL6 EST clone AI935298 EcoRI/HindIII digest (750 bp)
59-TGTTCACGCATTGCAGAGAGG-39
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Australian National Genome Information Service. The percentage iden-
tity between each of the 14 kallikreins was calculated using the Homol-
ogies tool on the Australian National Genome Information Service
website. Phylogenetic studies were also performed via the Australian
National Genome Information Service website. A distance matrix be-
tween the structures of the proteases was computed from the alignment
using the Dayhoff program of the Phylip package (31). The Neighbor-
joining method was then used to construct a tree from the distance
matrix.
Poly(A)1 RNA Dot Blot Analysis—For KLK1–4, 32P-end labeled oli-
gonucleotides were used to probe a CLONTECH Master blot containing
poly(A)1 RNA from 50 different human tissues. Hybridizations were
performed overnight in ExpressHybTM solution (CLONTECH) at 42 °C.
For KLK6–11 DNA fragments used in the poly(A)1 RNA dot blot anal-
yses were obtained by RT-PCR using the primers detailed in Table II.
RT-PCR was performed as described below for the screening of the
cancer cell lines. Amplicons were purified using a PCR purification kit
(Qiagen) and ligated into pGEM-T or pGEM-T Easy (Promega). DNA
insert orientation was examined by sequencing and restriction enzyme
digestion analysis. For KLK5 and KLK12–14, probes were generated
from EST clones accession number W07551, accession numbers
AI394679, AA002101, and AI935298 (Genome Systems Inc), respec-
tively. Prior to radioactive labeling each construct was linearized before
transcription using T7, T3, or SP6 RNA polymerase as appropriate to
generate an antisense cRNA. Radiolabeled cRNA probes were gener-
ated from these clones by incorporation of [32P]UTP (Geneworks) using
a StripEzTM kit (Ambion) and hybridized, in UltrahybTM solution (Am-
bion), to a Multiple Tissue Expression array (CLONTECH) containing
poly(A)1 RNA from 76 different human tissues and cell lines at 65 °C
overnight. All blots were washed in 0.1 3 SSC, 0.1% SDS up to 70 °C,
and signals were detected by exposure of the blot to x-ray film (AGFA
Curix Ortho) for 1–7 days at 280 °C. Control blots, containing DNA for
each of the 14 kallikreins, were included in each hybridization to
confirm the specificity of the radiolabeled probes.
Cell Lines and Tissue Samples—The following cell lines were ob-
tained from the American Tissue Culture Collection: T47D (breast
cancer cell line); HaCAT (keratinocyte cell line); OVCAR-3 (ovarian
cancer cell line); HEC1A, Ishikawa, and KLE (endometrial cancer cell
lines); and DU145, PC3, and LNCaP (prostate cancer cell lines). An
additional prostate cell line, ALVA41, was obtained from Dr. A. Nakla,
St Luke’s Hospital, New York. The normal kidney tissue samples and
the renal carcinoma cell lines, Caki1 and SN12k1, were a gift from Dr.
David Nicol, Princess Alexandra Hospital, Brisbane, Australia. The
prostate tissue samples were obtained during surgery by Dr. Robert
Gardiner, Royal Brisbane Hospital, Brisbane. The ovarian cancer cell
line, PEO1, was obtained from Dr. Michael McGuckin, Mater Medical
Research Institute, Brisbane. Salivary gland tissue total RNA was
purchased from CLONTECH and the human salivary gland cell line
was obtained from Dr. Ray MacDonald, University of Texas, South-
Western Medical Center, Dallas, TX. All cell lines were cultured in
Dulbecco’s modified Eagle’s medium with 10% deactivated fetal calf
serum and supplemented with 50 units/ml penicillin G and 50 mg/ml
streptomycin (CSL Biosciences) and incubated at 37 °C with 5% CO2.
RT-PCR and Southern Blot Analysis—Total RNA was extracted from
the cell lines using Trizol reagent (Life Technologies, Inc.) following the
manufacturer’s instructions. Two mg of total RNA was reverse-tran-
scribed into first-strand cDNA using Superscript II (Life Technologies,
Inc.) in a 20-ml reaction. The cDNA was subsequently diluted 5-fold and
PCR was then performed in a reaction mixture containing 1 ml of cDNA,
25 ng of each primer (Table II), 0.1 mM dNTPs (containing dATP, dCTP,
dGTP, and TTP), 2 ml of 10 3 reaction buffer (Roche Molecular Bio-
chemicals), 0.5 units of platinum Taq (Life Technologies), and sterile
water to 20 ml. The cycling conditions were 94 °C for 5 min to activate
the polymerase, followed by 35 cycles of 94 °C for 1 min, 62–68 °C for 1
min (depending on the target gene), 72 °C for 1 min, and a final exten-
sion at 72 °C for 7 min. Ten ml of the PCR mixture was electrophoresed
on a 2% agarose gel and visualized by ethidium bromide staining. The
resulting amplicons were analyzed by Southern blot hybridization us-
ing digoxigenin 39 end-labeled oligonucleotide probes (Table I), internal
FIG. 1. Identification of KLK-like genes by Southern blot anal-
ysis. EcoRI-digested BAC and cosmid DNA was hybridized with a
32P-end labeled degenerate oligonucleotide to the highly conserved re-
gion spanning the catalytic histidine of serine proteases. The blot was
washed in 0.1 3 SSC, 0.1% SDS at 55° then exposed to film for 13 days.
TABLE II
PCR primers
Primer pairs used for the detection of the 14 KLK genes by RT-PCR and for the generation of DNA fragments for KLK6–11, used in poly(A)1
RNA dot blot analyses. The percent difference in sequence between an individual primer and each of the 14 genes for all primers used averaged
74%.
Gene PCR primers Product size
KLK1/KLK1 Forward 59-TGGAGAACCACACCCGCCAAG-39 468 bp
Reverse 59-ACGGCGACAGAAGGCTTATTG-39
KLK2/KLK2 Forward 59-GCCTAAAGAAGAATAGCCAGGT-39 375 bp
Reverse 59-CTCAGACTAAGCTCTAGCACAC-39
KLK3/KLK3 Forward 59-GCATCAGGAACAAAAGCGTGA-39 138 bp
Reverse 59-CCTGAGGAATCGATTCTTCAG-39
KLK4/KLK4 Forward 59-GCGGCACTGGTCATGGAAAAGG-39 526 bp
Reverse 59-CAAGGCCCTGCAAGTACCCG-39
KLK5/KLKL2 Forward 59-GAGCTGGGGCCGGGGAAGAC-39 657 bp
Reverse 59-TGGGCCGGGCACAAGGGTAA-39
KLK6/Protease M Forward 59-GAGCGGCCATGAAGAAGC-39 459 bp
Reverse 59-AATCACCATCTGCTGTCTTGC-39
KLK7/SCCE Forward 59-GCCCAGGGTGACAAGATTATT-39 569 bp
Reverse 59-GTACCTCTGCACACCAACGG-39
KLK8/Neuropsin Forward 59-TACTCTGTGGCGGTGTCCTTG-39 523 bp
Reverse 59-GAGCCCCAGGATGTGATGCCC-39
KLK9/KLKL3 Forward 59-GGCCGGCCTCTTCCACCTTAC-39 678 bp
Reverse 59-GCGCGGGCTCAGTTCTCCAT-39
KLK10/Nes1 Forward 59-GCGGAAACAAGCCACTGTGGG-39 486 bp
Reverse 59-GGTAAACACCCCACGAGAGGA-39
KLK11/TLSP Forward 59-CCGCTACATAGTTCACCTGG-39 284 bp
Reverse 59-AGGTGTGAGGCAGGCGTAACT-39
KLK12/KLKL5 Forward 59-TGGCAGACAAAGAGACAAGGT-39 944/815 bp
Reverse 59-CTTAGAAGGGCTGGCAGGAG-39
KLK13/KLKL4 Forward 59-CTACACCTGCTTCCCCCACTCTCA-39 617 bp
Reverse 59-GCCGGTCAGGTTGCCCACAT-39
KLK14/KLKL6 Forward 59-CTGGGCAAGCACAACCTGAG-39 517 bp
Reverse 59-GCATCGTTTCCTCAATCCAGC-39
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to the PCR primers used, in EasyHybTM solution (Roche Molecular
Biochemicals) overnight at 37 °C. Washes were performed in 0.2 3 SSC,
0.1% SDS at 37 °C. In addition, for each kallikrein cDNA primer pair at
least one band of the predicted size was excised from a second 2%
agarose gel following electrophoresis. The DNA recovered from each
band was sequenced to determine the specificity of the PCR products.
Gene-specific Oligonucleotides—Gene-specific olionucleotides, used
as probes in the genomic and/or RT-PCR Southern blot analyses (Table
I) were selected from regions with maximum dyshomology among the
kallikreins based on a multiple sequence alignment of the 14 cDNAs.
The primers used in the PCR reactions (Table II) were designed to span
at least one intron for each of the 14 genes. The primer pairs were
chosen for their compatibility (i.e. no hairpin stem loops and similar
melting temperatures) and were found to be specific for the gene in
question upon BLAST analysis. In addition, the percent difference for
each primer/probe as compared with those of all the 14 genes was
calculated and found to range from 50 to 95%. The average percent
divergence for the oligonucleotides used as probes in the Southern blot
experiments was 70% whereas the average for the primers used in the
PCR was 74%.
FIG. 2. Fine mapping of KLK5–14 to
BAC and cosmid clones spanning the
KLK locus at 19q13.4. EcoRI-digested
BAC and cosmid DNA was hybridized
with 32P-end labeled oligonucleotides or
32P-random labeled cDNAs as described
in the text and detailed in Table I.
FIG. 3. Location of the KLK locus at chromosome 19q13.3–13.4. A, schematic representation of the interval between D19S425 and D19S418
including 19q13.3–13.4. The KLK locus is located proximal to D19S418. B, BAC and cosmid clones spanning the KLK locus. The position of the 14
kallikrein encoding genes are marked. C, in silico generated EcoRI digest data for BC85475 and BC349237 containing KLK4 to KLK14. Fragments
marked with an asterisk are either incomplete end fragments or have not been clearly determined because of the provisional status of the sequence.
The size of fragments obtained by Southern blot analysis data (see text and Fig. 2) is consistent with the in silico data. The position and orientation
of KLK1 to KLK4 on cosmids F24242, F25479, F22702, and R28781 have been reported previously (21). KLK4 to KLK14 are transcribed telomere
to centromere as indicated by the arrow at the bottom of the figure. The position of microsatellite markers are indicated in B and C.
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RESULTS
Characterization of an Extended KLK Locus at Chromosome
19q13.4—To determine if there were additional kallikrein
genes surrounding the original KLK locus on chromosome
19q13.3-13.4, Southern blot analysis was performed using de-
generate oligonucleotides to consensus sequences spanning the
catalytic histidine and serine residues characteristic of serine
proteases. A combination of 10 BACs and cosmids, which span
400–500 kb on either side of the original KLK 60-kb locus, were
digested with EcoRI and subsequently hybridized separately
with each of the 32P-labeled degenerate oligonucleotides. The
autoradiograph resulting from hybridization with the degener-
ate “histidine” probe demonstrated positive signals within five
of the BACs and cosmids (Fig. 1). Three of these clones
(BC33747, F22702, and R28781) contain the genes, KLK1–4
(21). However, a further two BACs (BC85745 and BC349237)
also showed strong hybridization to these probes. These were
not known to contain any serine protease genes. BC892989,
which lies telomeric to the KLK cluster and the 4 clones cen-
tromeric to the cluster (R31381, R32740, BC778306, and
BC772576) did not produce any positive signals even though
the membrane was exposed for 13 days. The degenerate “ser-
ine” oligonucleotide probe could not be used successfully in
these experiments, probably because of its degeneracy (512-
fold). Thus, additional serine protease genes are only found
within a region encompassed by BACs BC85745 and
BC349237, and there are no other serine protease genes ap-
proximately 200 kb telomeric of BC349237 and 400 kb centro-
meric of the original KLK1–3 cluster.
In order to identify the serine protease genes which were
detected using the degenerate probe described above, the same
set of EcoRI-digested BACs and cosmids were examined using
one or two gene-specific oligonucleotides or a cDNA probe to
each of the KLK5-14 genes. The KLK5 probe hybridized to a
14.5-kb fragment on BC85745 (Fig. 2). Positive signals were
detected on BC85745 at 10 and 6.5 kb for KLK6 and at 15 kb for
KLK7. A signal was observed for KLK8 on both BC85745 and
BC349237 at 10.5 and 2 kb, respectively, and KLK9 was found
to be located within three of the EcoRI fragments at 10, 3.5, and
1.8 kb on BC349237. Two bands at 18 and 10 kb were detected
for KLK10 on BC349237 whereas only the 18-kb band was
positive for KLK11. The remaining three KLK-like genes were
all present on BC349237. KLK12 was present on an 18-kb
band. Although only one signal (at approximately 5 kb) was
detected for KLK13, this band represents two individual EcoRI
fragments of 5.7 and 4.6 kb in size. The KLK14 cDNA probe
hybridized to an 18- and a 12-kb band.
Concurrent with the physical mapping studies, computer
analysis was performed on approximately 320 kb of draft
genomic sequence spanning the KLK locus on chromosome 19q.
FIG. 4. Phylogenetic tree of the ex-
panded KLK family. The tree was gen-
erated from an Eclustal multiple se-
quence alignment of the 14 kallikrein
proteins using the Dayhoff program of the
Phylip package.
TABLE III
Percentage homology between each member of the human kallikrein family at the protein level
hK1 hK2 hK3 hK4 hK5 hK6 hK7 hK8 hK9 hK10 hK11 hK12 hK13 hK14
hK1 100 67 62 34 31 37 37 36 35 31 36 27 37 39
hK2 100 77 34 33 41 38 38 36 33 36 27 41 40
hK3 100 34 33 36 37 36 34 31 34 26 40 38
hK4 100 45 36 43 35 31 29 35 25 35 40
hK5 100 36 38 38 38 33 39 25 38 39
hK6 100 38 42 36 34 38 32 46 45
hK7 100 40 33 36 36 28 38 41
hK8 100 42 40 42 33 41 44
hK9 100 33 49 29 37 40
hK10 100 35 31 34 35
hK11 100 30 41 40
hK12 100 31 30
hK13 100 43
hK14 100
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To identify novel protease genes in this region, searches of the
genomic sequence were performed using the consensus se-
quences spanning each of the histidine, aspartate, and serine
residues necessary for the enzymatic activity of serine pro-
teases. These searches identified 10 potential serine protease
genes in addition to known kallikrein genes, KLK1–4. Further
searches were then performed with the sequence for each of the
KLK-like serine protease genes: Protease M (KLK6), SCCE
(KLK7), neuropsin (KLK8), Nes1 (KLK10), TLSP (KLK11),
KLKL2 (KLK5), KLKL3 (KLK9), KLKL4 (KLK13), KLKL5
(KLK12), and KLKL6 (KLK14), using the BLASTN algorithm.
All 10 of these genes were identified within this sequence and
were found to correspond to the genes identified from searches
using the three serine protease consensus sequences. The
genes were all located in a telomeric position with respect to
the KLK2–4 genes. The KLK1 gene is located ;31 kb centro-
meric of KLK2–4 (21, 22); sequence data is not available for
this region. Also, an EcoRI restriction map of the sequence
contained within BACs BC85745 and BC349237 was con-
structed in silico. This map was used in conjunction with the
physical mapping data and the EcoRI map available at the
Lawrence Livermore National Laboratory website, to deter-
mine the exact position of each gene and to reconstruct a
definitive EcoRI map of this region (Fig. 3). The size of each
of the bands identified by Southern blot analysis (Fig. 2)
agreed with the in silico generated EcoRI fragment sizes. From
the map, the order of the expanded KLK locus (according to the
old nomenclature) is centromere-KLK1-KLK3-KLK2-KLK4-
KLKL2-Protease M-SCCE-neuropsin-KLKL3-Nes1-TLSP-
KLKL5-KLKL4-KLKL6-telomere (new nomenclature: centro-
mere-KLK1-KLK3-KLK2-KLK4- to -KLK14-telomere). Analysis
of the contiguous sequence indicated that KLK5 to KLK14 are
transcribed telomere to centromere (Fig. 3).
Clarification of the Position of Microsatellite Markers within
the KLK Locus at Proximal 19q13.4—To clarify the order and
position of the microsatellite markers within the KLK locus,
microsatellite marker sequences were aligned against the chro-
mosome 19q proximal 13.4 draft sequence data using the
BLASTN algorithm. For this purpose, a data base of contiguous
sequence was established using the resources available at the
FIG. 5. mRNA expression patterns. Membranes containing poly(A)1 from human tissues and cell lines were screened with 32P-labeled probes
to each of the 14 KLK genes. Autoradiographs representative of the patterns obtained are shown. A, KLK1. B, KLK2–4. C, KLK10. D, KLK11.
Tissues arrayed on the membranes in panels A and B: A1, whole brain; A2, amygdala; A3, caudate nucleus; A4, cerebellum; A5, cerebral cortex;
A6, frontal lobe; A7, hippocampus; A8, medulla oblongata; B1, occipital lobe; B2, putamen; B3, substantia nigra; B4, temporal lobe; B5, thalamus;
B6, nucleus accumbeus; B7, spinal cord; C1, heart; C2, aorta; C3, skeletal muscle; C4, skeletal muscle; C5, bladder; C6, uterus; C7, prostate; C8,
stomach; D1, testis; D2, ovary; D3, pancreas; D4 pituitary gland; D5 adrenal gland; D6, thyroid gland; D7, salivary gland; D8, mammary gland;
E1, kidney; E2, liver; E3, small intestine; E4, spleen; E5, thymus; E6, peripheral blood leukocyte; E7, lymph node; E8, bone marrow; F1, appendix;
F2, lung; F3, trachea; F4, placenta; G1, fetal brain; G2, fetal heart; G3, fetal kidney; G4, fetal liver; G5, fetal spleen; G6, fetal thymus; G7, fetal
lung; H1, yeast total RNA, 100 ng; H2, yeast tRNA, 100 ng; H3, Escherichia coli rRNA, 100 ng; H4, E. coli DNA, 100 ng; H5, Poly r(A) 100 ng; H6,
human C0t-1 DNA, 100 ng; H7, human DNA, 100 ng; H8, human DNA, 500 ng. Tissues arrayed on the membranes in panels C and D: A1, whole
brain; A2, cerebellum, left; A3, substantia nigra; A4, heart; A5, esophagus; A6, colon; A7, kidney; A8, lung; A9, liver; A10, leukemia, HL-60; A11,
fetal brain; A12, yeast total RNA; B1, cerebral cortex; B2, cerebellum, right; B3, accumbens nucleus; B4, aorta; B5, stomach; B6, colon, descending;
B7, skeletal muscle; B8, placenta; B9, pancreas; B10, HeLa S3; B11, fetal heart; B12, yeast tRNA; C1, frontal lobe; C2, corpus callosum; C3,
thalamus; C4, atrium, left; C5, duodenum; C6, rectum; C7, spleen; C8, bladder; C9, adrenal gland; C10, leukemia, K-562; C11, fetal kidney; C12,
E. coli rRNA; D1, parietal lobe; D2, amygdala; D3, pituitary gland; D4 atrium, right; D5 jejunum; D7, thymus; D8, uterus; D9, thyroid gland; D10,
leukemia MOLT-4; D11, fetal liver; D12, E. coli DNA; E1, occipital lobe; E2, caudate nucleus; E3, spinal cord; E4, ventrical, left; E5, ileum; E7,
peripheral blood leukocyte; E8, prostate; E9, salivary gland; E10, Burkitt’s lymphoma, Raji; E11, fetal spleen; E12, Poly r(A); F1, temporal lobe;
F2, hippocampus; F4, ventrical, right; F5, ilocecum; F7, lymph node; F8, testis; F9, mammary gland; F10, Burkitt’s lymphoma, Daudi; F11, fetal
thymus; F12, human C0t-1 DNA; G1, cerebral cortex; G2, medulla oblongata; G4 interventricular septum; G5, appendix; G7, bone marrow; G8,
ovary; G10, colorectal adenocarcinoma, SW480; G11, fetal lung; G12, human DNA 100 ng; H1, pons; H2, putamen; H4, apex of heart; H5, colon,
ascending; H7, trachea; H10, lung carcinoma, A549; H12, human DNA 500 ng.
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Australian National Genome Information Service website.
Marker sequences between 272.77 and 276.46cR3000 at interval
D19S425-D19S418 on chromosome 19 were aligned with the
nucleotide sequence within the data base. The data obtained
from these searches was used to re-evaluate the order and
presence of these markers within the region of the KLK locus
(Fig. 3). Markers WI-9055 and M21896, previously recognized
as partial KLK3 sequence, as well as U37672 (previously un-
known) were all found to lie within the KLK3 sequence on
cosmid F25479. The two markers previously identified as par-
tial KLK1 sequence, stSG39975 and sts-S39329, are actually
partial sequences of the KLK2 gene and were found within the
sequence of R33359 which overlaps cosmid F22702 at this
location. The marker, WI-20869, recognized as KLK6 partial
sequence, was confirmed to lie within the KLK6 coding se-
quence on BC85745. Similarly, stSG30247 was shown to lie
within the KLK10 sequence on BC349237. In contrast, none of
the remaining microsatellite markers listed as being located in
the interval D19S425-D19S418 were detected within the avail-
able genomic sequence of the extended KLK locus. These mark-
ers are stSG32045 (EST), stSG1457 (b-Electron transfer fla-
voprotein), stSG3375 (OTK18 mRNA), stSG372 (CD33
antigen), sts-H71236 (EST), SGC35527 (granulocyte colony
stimulating factor-induced gene), U37672 (unknown),
stSG30429 (EST), sts-AA028917 (EST, highly similar to zinc
finger protein 91), L12214 (unknown). Prior mapping work
shows genes CD33 and ETFB to be distal to the KLK locus by
;40 and ;250 kb, respectively.
Divergence of Serine Protease Genes within the Extended
KLK Locus—Protein alignments were performed to establish
the degree of similarity and divergence of the 14 serine prote-
ase genes located within the expanded KLK locus. The percent-
age homology between the proteins encoded by the 14 KLK
genes was also calculated (Table III). The classical KLK family
members, hK1,3 hK2 and PSA (encoded by KLK1, KLK2, and
KLK3, respectively), display a high degree of homology (62–
77% identity) at the protein level. hK4, is less similar with only
34% identity to PSA. As shown in Table III, hK4 possesses a
similar degree of homology to the more recently identified
serine proteases hK5-14 (25–45%) as it does to PSA. Similarly,
the degree of homology between the protease groups, hK5–14
and hK1–3, ranges from 26 to 41%. Phylogenetic analysis of the
14 protein sequences produced similar results to the homology
studies (Fig. 4). The phylogenetic tree demonstrated that hK1,
hK2, and PSA lie on one branch, as do hK4, hK5, and hK7. The
two serine proteases, hK10 and hK12, were clustered on a third
branch while hK9 and hK11 were found on a fourth branch.
However, the remaining four members (hK6, hK8, hK13, and
hK14) were located around the base of the tree. Due to the low
branch numbers assigned to these four kallikreins, it is difficult
to precisely determine their degree of divergence from the
family as a whole. Nevertheless, the high branch numbers
observed overall suggest that this expanded family of human
kallikreins consist of at least four subfamilies.
mRNA Expression Patterns—To establish a comprehensive
pattern of expression for the 11 KLK genes, KLK4–14, as
compared with that known for KLK1–3, arrays containing
poly(A)1 RNA from either 50 or 76 different human tissues and
cell lines were screened using 32P-labeled probes to each of the
14 KLK serine protease genes. Examples of the autoradio-
graphs obtained are shown in Fig. 5 and a summary of the
expression levels is shown in Table IV. The expression patterns
observed for KLK1–4 were as previously reported, where KLK1
was detected in the kidney, pancreas, and salivary gland while
KLK2–4 were present only within the prostate (27, 32, 33).
High expression of the KLK10 gene was observed in the pan-
creas and moderate expression in the esophagus, duodenum,
trachea, and colorectal adenocarcinoma. Low expression was
seen in tissues such as the liver, kidney, ovary, testis, prostate,
and salivary gland. High expression of KLK11 was also de-
3 Kallikrein family protein nomenclature used here is that described by Berg et al. (3), e.g. protein hK1 corresponds to gene KLK1.
TABLE IV
Summary of mRNA expression patterns
Membranes containing poly(A)1 from human tissues and cell lines were screened with 32P random labeled probes to each of the 14 kallikreins.
Gene High expression Moderate expression Gene High expression Moderate expression
KLK1 Kidney KLK8 Pancreas Duodenum
Pancreas (Neuropsin) Liver
Salivary gland Esophagus
Stomach
Salivary gland
KLK2 Prostate KLK9 Pancreas
(KLKL3)
KLK3 Prostate KLK10 Pancreas Esophagus
(Nes1) Duodenum
Trachea
Colorectal adenocarcinoma
KLK4 Prostate KLK11 Pancreas Heart
(TLSP) Salivary gland
Stomach
Liver
Skeletal muscle
KLK5 Testis Salivary gland KLK12 Pancreas Brain
(KLKL2) Mammary gland Esophagus (KLKL5) Duodenum
Appendix
KLK6 Pancreas Spinal cord KLK13 Pancreas Duodenum
(Protease M) Brain (KLKL4) Esophagus Stomach
Testis Appendix Brain
Appendix Testis
Colorectal adenocarcinoma Prostate
Salivary gland
KLK7 Pancreas KLK14 Brain Liver
(SCCE) (KLKL6) Bone marrow Pancreas
Fetal liver Fetal spleen
Prostate
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tected in the pancreas. Moderate expression of KLK11 was
observed in the heart, salivary gland, stomach, liver, and skel-
etal muscle, while low expression was observed in most of the
remaining tissues represented on the blot. Of interest, is the
overall high expression of nearly all of these new KLK genes in
the pancreas, particularly KLK6 to KLK13. Furthermore, mod-
erate expression was observed for several genes in the salivary
gland, esophagus, trachea, brain, gastrointestinal, and repro-
ductive organs.
In addition, RT-PCR was performed using total RNA ex-
tracted from a number of different transformed and cancer cell
lines as well as normal and cancer tissues. To increase the
sensitivity of detection, Southern blot analysis using gene-
specific oligonucleotide probes was performed on the PCR prod-
ucts as shown in Fig. 6 and summarized in Table V. To confirm
the specificity of the PCR for each of the 14 genes, bands of the
predicted size were sequenced and found to correspond to the
gene of interest (see Table V). From these results, it can be seen
that each gene displays a distinctive expression pattern with
several genes (KLK1, KLK6, KLK7, KLK9, KLK10, KLK11,
KLK13, and KLK14) being expressed in a broad range of tis-
sues/cell lines whereas other genes (KLK2–5, KLK8, and
KLK12) are less widely expressed. Of interest is the high ex-
pression of many of the newer KLK genes (KLK5–14) in kera-
tinocyte (HaCAT), ovarian (OVCAR-3 and PEO1), breast
(T47D), and endometrial (KLE) cancer cell lines. In addition,
all genes (except for KLK12) appear to have varying levels of
expression in one of the four prostate cancer cell lines. Further-
more, several of these genes are moderately expressed in the
salivary gland and kidney. Additional bands were observed for
several of the genes being examined. Some of these alternate
bands were sequenced and found to represent variants of the
gene in question (data not shown). Similarly, other studies
have identified alternatively spliced transcripts for these new
KLK genes (19).
DISCUSSION
The tissue kallikrein genes, particularly those in rodents,
represent a distinctive family of a large number of genes, which
are highly conserved in sequence and genomic organization.
Nevertheless, the encoded enzymes exhibit specific tissue ex-
pression patterns and diverse biological functions. We have
now determined that the size of the human KLK gene family,
like its rodent counterparts, is large and it is likely to consist of
14 genes. Physical mapping of these genes at chromosome
19q13.4 concurs with recent computer analysis of draft se-
quence data of this region (30). The tissue-specific patterns of
expression observed for these 14 genes shows, again like ro-
dents, a diverse expression profile for individual members of
the family. Of interest, however, is that the human family has
diverged further in sequence.
The rodent KLK families are very large with 13 genes in the
rat and 24 genes in the mouse (23–25) and both cluster to one
chromosomal loci (23, 25, 26). The original human KLK family
(KLK1–3), also clustered to one loci (21, 22), has a high degree
of similarity to the rodent family with 65–72% identity at the
nucleotide level. Due to the similarity between these KLK
families and the previous report by Murray et al. (29), which
proposed the existence of up to 19 human KLK genes by screen-
ing human genomic DNA with a monkey cDNA, we began the
search for new members of the human KLK family. In addition,
previous studies placed the genes encoding the serine proteases
Protease M and Nes1 (KLK6 and KLK10 respectively), on chro-
mosome 19q in a region to which the original kallikreins,
KLK1–3, also map (10, 13).
Our initial studies involving Southern blot analysis identi-
fied several potentially novel serine protease genes within the
surrounding regions of chromosome 19q. Further investigation
of these results identified five published serine protease genes
(previously named Protease M, Nes1, TLSP, SCCE, and Neu-
ropsin) on the BACs and cosmids containing the human KLK
genes, KLK2-4. All five genes were detected telomeric to KLK4
and thus were considered to be candidates for new members of
the human KLK family. Furthermore, several other KLK-re-
lated sequences, KLK5, KLK9, and KLK12–14, were also phys-
ically mapped to 19q13.4. This confirmed the recently pub-
lished data identifying the position of these genes on
chromosome 19, by computer analysis (30). In addition, as the
data obtained by Southern blot analysis with a degenerate
probe to the histidine-encoding region of serine proteases, de-
tected unaccounted for signals only within the two BACs adja-
cent to the classical KLK locus (BC85745 and BC349237) and
no signal from DNA, both telomeric to these two BACs or
centromeric to the original KLK cluster, it would appear that
there are only 10 additional serine protease genes within the
surrounding regions of the classical KLK locus. In accordance
with our data, the next gene telomeric from KLK14 (KLK-L6) is
an unrelated gene, OB-BP-like, and encodes a putative leptin-
binding protein (34). Accordingly, although sequence is not yet
available for the region centromeric to KLK1, it is likely the
complete KLK locus has now been identified.
FIG. 6. Expression pattern analysis by RT-PCR. Analysis was
performed on total RNA isolated from the displayed cell lines and
tissues using the primers listed in Table II. RT-PCR products were
transferred to nylon membranes and probed by Southern blot analysis
using digoxigenin-labeled oligonucleotide probes (Table I) internal to
the PCR primers used. SG, salivary gland.
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Comparison of the rat KLK gene sequences indicates con-
certed evolution of the family that results in sequence homog-
enization of all family members (35). In addition, there is a
clear conservation of genomic organization with 5 coding exons
for all KLK genes, although some of the newer family members
have additional exons containing 59-untranslated sequences (6,
7, 10, 13, 15–21, 23, 27). Characterization of the mouse and rat
KLK genes showed that nucleotide sequence identity exceeds
85% and extends throughout the coding regions, introns, and
gene flanking sequences (23, 24, 35). The first characterized
human KLK family members, KLK1–3, also show high se-
quence homology, at both the nucleotide and protein level (62–
77%) (6, 7, 23, 32). However, in man the level of homology drops
sharply for kallikrein genes telomeric of KLK1–3. The next
closest gene along the locus, KLK4 (15, 21), is 34% identical to
KLK3 (15, 21, 27). Similarly, as reported here and by others,
the newer members of the family (KLK5–14) are less conserved
with 25–49% similarity at the protein level, both between each
other and with respect to KLK1-KLK4 (10, 13, 15–20). This
divergence was also evident from our phylogenetic analysis.
The degree of divergence seen within the human KLK family
tree suggests that there are a number of subgroups within this
species. The mouse Klk and original human KLK gene families
were shown to lie in syntenic regions on chromosomes 7 and
19q, respectively (21–23). Of interest, the putative mouse or-
thologue of one of the newer human KLK genes, KLK8 (neu-
ropsin), also maps to this region on chromosome 7 (36).
Analysis of microsatellite markers within the KLK locus
showed that the current order needed to be revised. Alignment
of each of the markers with the genomic sequence for chromo-
some 19q revealed that a number of the genes listed were in
fact not found within the sequence available spanning the KLK
locus. Nevertheless, those markers representative of partial
KLK2, KLK3, KLK6, and KLK10 gene sequences were indeed
detected within the genomic sequence. Thus, the listing of the
microsatellite markers within the KLK locus has now been
further clarified.
Poly(A)1 RNA dot blot analysis indicated the prostate-re-
stricted expression of KLK2–4 and abundant expression of
KLK6–13 in pancreas. Of interest, in an analogous fashion to
the mouse and rat clustered Klk/KLK genes which are predom-
inantly expressed in the salivary gland (9, 23), KLK2–4 are
clustered together within the human locus as are KLK6–13.
Furthermore, in man the two genes displaying high expression
in the testis/mammary gland and brain/bone marrow/fetal
liver, KLK5 and KLK14, respectively, are located either side of
the cluster of pancreatic-expressed genes. As the KLK5 gene
lies adjacent to the KLK2–4 cluster, also found in a hormone-
dependent tissue, these four genes may also share common
transcriptional control elements. As has been suggested for the
rat kallikreins (9, 24, 35), this clustering of genes having com-
mon restricted expression patterns likely indicates evolution-
ary conservation of elements conferring tissue specificity such
as duplicated promoter elements or a locus control region.
Whether KLK transcriptional control in man is conferred
through either or both of these elements is not yet known.
Certainly our phylogenetic studies indicate that the human
kallikreins have diverged to a much greater extent than the
comparably sized rodent families. This observation may indi-
cate that duplicated promoter elements would not be expected
to have survived the apparent evolutionary pressure to diverge
in man or, alternatively, may account for variations in expres-
sion patterns. Of interest, a pancreatic-specific-like sequence,
similar to that identified in other rat pancreatic serine pro-
teases (37, 38), has been identified in the promoter of the rat,
mouse, and human KLK1 genes (24). In contrast, duplicated
promoter regions have already been identified in the KLK2 and
KLK3 genes (39, 40). In addition, although expression profiles
of rat kallikreins show that individual genes are expressed in
diverse tissue-specific patterns there is still high conservation
of potential transcriptional regulatory regions (24, 25).
Our RT-PCR analysis of the cell line expression patterns of
KLK5–14 indicated that most of these genes display significant
expression in keratinocytes, breast, ovarian, and endometrial
cancer cell lines and in salivary gland tissue and a salivary
gland cell line. Expression of these KLKs in cancer-derived and
transformed cell lines is not surprising, and concurs with other
studies (10, 11, 13–21, 27, 34, 43), as proteases are well known
to aid in malignant processes such as invasion, metastasis, and
proliferation (41, 42). It will be of interest to determine whether
any of the kallikreins are up-regulated in tumors and the role
of these proteolytic enzymes in tumor progression.
Although the enzymic function of these newer kallikrein
enzymes is yet to be elucidated, an indication of the tissue in
which they will be functional may be gained from the patterns
of expression noted above. From several in vitro biochemical
studies, PSA and hK2 are known to degrade extracellular ma-
trix proteins and PSA degrades the insulin-like growth factor-
binding protein 3 to regulate the bio-availability of insulin-like
growth factor 1; a key factor in cancer cell proliferation (8, 44).
TABLE V
Expression patterns of the 14 KLK genes obtained by RT-PCR analysis
The following symbols used represent: 111, high expression; 11, moderate expression; 1, low expression; (}) PCR products of the predicted
size sequenced and confirmed to be the correct sequence.
Cell line KLK1 KLK2 KLK3 KLK4 KLK5KLKL2
KLK6
protease M
KLK7
SCCE
KLK8
neuropsin
KLK9
KLKL3
KLK10
Nes1
KLK11
TLSP
KLK12
KLKL5
KLK13
KLKL4
KLK14
KLKL6
T47D 11 111 111 11} 1 111 11 1 11 111
HaCAT 1 1 111 111 111} 11 111} 111} 11 111
HEC1A 111} 1 11 11 1 111} 1
Ishikawa 111 11} 11 1 11 111
KLE 11 11 111 111 111 111 1 111 111 111 1
Prostate tissue 11 111} 111} 111} 11 1 111 111 1
Prostate tissue 1 111 111 111 11 1 111
SG tissue 11 1 11 11 11 11 1 111 11
SG cell 11 1 11 1 111} 11 111
Kidney tissue 111} 1 11 111} 11 1 1 1
Caki1 111 111
Sn12K1 111 11 1 1 1 1
OVCAR-3 111 111 111} 111 11 111} 11} 111 111 11} 111}
PEO1 111 1 111 111} 111} 111 111 111} 111} 11 111
ALVA 1 111 1 1
DU145 1 1 111 111 11 11 1 1
PC3 1 1 111 11 11 11 1 111
LNCaP 1 11 1 1 111
Tissue-specific Expression and Mapping of Human KLK Genes 37405
 at UQ Library on October 19, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
The hK2 enzyme is likely the physiological activator of PSA (8)
and hK2 can also activate urokinase plasminogen activator
(45), another key enzyme in matrix degradation, demonstrat-
ing that involvement in an enzymic cascade may also be an
important function of this family of enzymes. Both PSA and
hK2 are useful diagnostic and prognostic markers in prostate
and breast cancer (8, 34). Thus, many of the newer members of
the KLK family which are all expressed in a variety of cancer
cell lines may have similar functional roles in these diseases.
Similarly, other new KLK members, which are highly ex-
pressed in skin and brain, have been suggested to play impor-
tant roles in the (patho)physiology of these organs (12, 46–48).
The high pancreatic and gastrointestinal tract expression of
several KLK genes may also prove to be of significance since
tissue kallikrein has already been shown to play a role in the
(patho)physiology of these tissues (2, 49).
In summary, we have physically mapped the KLK locus,
providing a definitive fine map of this region at 19q13.4 and
have further clarified the size and expression patterns of the
extended human KLK gene family. Our tissue mRNA expres-
sion studies indicate KLK expression can be largely delineated
between those having prostate restricted expression (KLK2–4)
and those having abundant pancreas expression (KLK6–13).
These profiles suggest evolutionary conservation of elements
conferring tissue specificity such as duplicated promoter ele-
ments and locus control regions. Future studies will be directed
at characterizing these elements and in elucidating the roles of
kallikrein serine proteases in human biology and disease.
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